Empowered Patient Podcast
Allogeneic CAR-T Immunotherapies Showing Promise for Solid Tumors with Filippo Petti Celyad
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:16:15
- More information
Informações:
Synopsis
Filippo Petti, CEO, Celyad discusses how the company is broadening precision medicine by developing CAR-T immunotherapies to express a natural killer receptor that can recognize and target multiple ligands expressed in up to 80% of all cancers. Filippo talks about the value to cancer patients of both personalized (autologous) and off the shelf (allogeneic) CAR-T therapies and CYAD-101, Celyad's allogeneic CAR-T therapy, that demonstrated for the first time ever, clinical effectiveness in solid tumors. @CelyadSA #CAR_T #NKCells #cancer #immunotherapy #CellTherapy #solidtumors #Tcell #CYAD101 #allogeneic $CYAD Celyad.com Download the transcript here
